2026-08-14T13:18:53-05:00 2025-09-30 911194016 CLARK NUBER PS 555 110TH AVE NE SUITE 700 BELLEVUE WA 98004 990 2024-10-01 910667886 PACIFIC NORTHWEST RESEARCH INSTITUTE PACI 2067261200 720 BROADWAY SEATTLE WA 98122 DIONNE GORDON CFAO 2067261200 2026-08-12 1 0 MEGAN R RYAN P00737884 4254544919 2026-08-12 2024 2025-03-06 01:10:19Z DIONNE GORDON 720 BROADWAY SEATTLE WA 98122 7229078 0 X WWW.PNRI.ORG X 1956 WA AN INDEPENDENT, BIOMEDICAL RESEARCH INSTITUTE AIMED AT UNDERSTANDING HOW HEALTH IS MAINTAINED IN THE FACE OF GENETIC AND ENVIRONMENTAL RISKS ASSOCIATED WITH DISEASE DEVELOPMENT. 15 14 71 16 0 0 5105774 5881536 12513 886319 133214 286535 216303 154368 5467804 7208758 18127 0 0 0 7057078 6080333 0 0 570002 3784848 3579609 10860053 9659942 -5392249 -2451184 13215750 13818502 886167 3497216 12329583 10321286 X PACIFIC NORTHWEST RESEARCH INSTITUTE (PNRI), A NONPROFIT CORPORATION, IS AN INDEPENDENT, BIOMEDICAL RESEARCH INSTITUTE CONDUCTING BASIC AND APPLIED RESEARCH AIMED AT UNDERSTANDING HOW HEALTH IS MAINTAINED IN THE FACE OF GENETIC AND ENVIRONMENTAL RISKS ASSOCIATED WITH DISEASE DEVELOPMENT. THE SCIENTIFIC DISCOVERIES HAVE APPLICABILITY IN A VARIETY OF DISEASES, INCLUDING DIABETES, CANCER, NEUROLOGICAL DISORDERS, AMONG MANY OTHERS. 1 1 1763218 EXPERIMENTING IN YEAST ALLOWS THE DUDLEY LAB TO MAKE DISCOVERIES THAT GO BEYOND THE LAB WITH THE POWER TO CHANGE HOW SCIENTISTS AROUND THE GLOBE APPROACH GENETIC RESEARCH. FROM PERFORMING LARGESCALE EXPERIMENTS TO DISCOVERING NEW ANTIFUNGAL TREATMENTS, THE DUDLEY LAB IS A WORLD LEADER IN USING YEAST TO ANSWER FUNDAMENTAL QUESTIONS ABOUT BIOLOGY. WE ARE PASSIONATE ABOUT APPLYING AND DEVELOPING NOW TECHNOLOGIES AND ABOUT TRANSLATING DISCOVERIES FROM OUR LAB INTO REALWORLD APPLICATIONS. THE DUDLEY LAB EXPERIMENTS IN YEAST BECAUSE YEAST CELLS FUNCTION IN MUCH THE SAME WAY AS HUMAN CELLS. HOWEVER, WITH YEAST, WE CAN PERFORM EXPERIMENTS MUCH FASTER, AND ON A GRANDER SCALE, THAN SCIENTISTS CAN WITH HUMAN CELLS. 1689533 886319 THE HAGOPIAN LAB RESEARCHES WAYS TO PREDICT AND PREVENT THE DEVELOPMENT OF TYPE 1 DIABETES, A DISEASE AFFECTING OVER ONE MILLION AMERICAN CHILDREN AND ADULTS. NOT EVERYONE WITH GENETIC RISK FOR TYPE 1 DIABETES DEVELOPS THE DISEASE. WHY NOT? SCIENTISTS IN THE HAGOPIAN LAB BELIEVE ANSWERS LIE IN THE ENVIRONMENT. THEY ARE ONE OF 6 LABS PARTICIPATING IN AN INTERNATIONAL STUDY FOLLOWING 8,000 CHILDREN WITH HIGH GENETIC RISK FOR TYPE 1 DIABETES. THE HAGOPIAN LAB ALSO DEVELOPS POPULATION BASED NEWBORN SCREENING METHODS TO PREDICT WHO IS AT RISK. THE ULTIMATE GOAL IS TO PREVENT THE DISEASE ENTIRELY. 1345160 THE CARVALHO LAB STUDIES HOW, WHEN, AND WHY HUMAN GENOMIC VARIANTS OCCUR AND CONTRIBUTE TO THE DEVELOPMENT OF DISEASE AND DISABILITY. 1241252 THE METZGER LAB IS MAKING DISCOVERIES ABOUT HOW CANCERS MUTATE AND EVOLVE BY STUDYING CONTAGIOUS CANCERS IN MARINE BIVALVES, AND THEY ARE LEARNING HOW SOME CLAMS HAVE EVOLVED THE ABILITY TO BLOCK THE CANCERS THAT INFECT THEM, WHICH MAY HELP US UNDERSTAND HOW OUR BODIES CAN RESIST CANCER. 1241252 6039163 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 24 0 71 1 0 0 0 0 0 0 0 0 0 0 0 0 X 15 14 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 WA X DIONNE GORDON 2067261200 720 BROADWAY SEATTLE WA 98122 JOHN FARIS CEO THRU 06/25, BOARD MEMBER 18.00 X X 218042 0 0 GARY KOCHER BOARD CHAIR 2.00 X X 0 0 0 MATTHEW GAGNIER TREASURER 1.00 X X 0 0 0 TOM HAYWARD SECRETARY 1.00 X X 0 0 0 KELLIE BICKEL BOARD MEMBER 0.50 X 0 0 0 JUSTIN BROOKS BOARD MEMBER 0.50 X 0 0 0 ELENA CANT BOARD MEMBER 0.50 X 0 0 0 TERA EERKES BOARD MEMBER 0.50 X 0 0 0 CINDY HABA BOARD MEMBER 0.50 X 0 0 0 DAVID MARTINEZ BOARD MEMBER 0.50 X 0 0 0 STEPHAN MARTINEZ BOARD MEMBER 0.50 X 0 0 0 LINDA MAUZY CHAIR OF GOVERNANCE COMMITTEE 1.00 X 0 0 0 SHIRIN MCCONAGHY BOARD MEMBER 0.50 X 0 0 0 ERICK RABINS BOARD MEMBER 0.50 X 0 0 0 PAUL REED BOARD MEMBER 0.50 X 0 0 0 REBECCA CAMPBELL BOARD MEMBER THRU 04/25 0.50 X 0 0 0 DIONNE GORDON CFAO 40.00 X 277618 0 9682 AIMEE DUDLEY PRINCIPAL INVESTIGATOR 40.00 X 266065 0 30500 CLAUDIA FONSECA PRINCIPAL INVESTIGATOR 40.00 X 151810 0 4734 RICHARD MCLAUGHLIN PRINCIPAL INVESTIGATOR 40.00 X 170169 0 23000 MICHAEL METZGER PRINCIPAL INVESTIGATOR 40.00 X 169445 0 27149 LISA STUBBS PRINCIPAL INVESTIGATOR THRU 12/24 40.00 X 236225 0 30500 SHANNON BOWEN CHIEF ADVANCEMENT OFFICER 40.00 X 240894 0 27149 JUSTIN DUKES DIRECTOR IT 40.00 X 155685 0 11060 MICHAEL KILLIAN CLINICAL DIRECTOR 40.00 X 148568 0 11281 LOUISE MAXWELL CHIEF COMMUNICATIONS OFFICER 40.00 X 135750 0 23346 SRIVIDYA VENKATESH CONTROLLER 40.00 X 132082 0 23000 LISA LATENDRESSE DIRECTOR OF HUMAN RESOURCES 40.00 X 131567 0 3985 2433920 0 225386 16 0 1 0 BENDER & FROST 1702 COLE STREET ENUMCLAW WA 98022 IT CONSULTING 327979 KNOBBE MARTENS OLSON & BEAR LLP 2040 MAIN STREET FLOOR 14 IRVINE CA 92614 LEGAL 136389 DORSEY & WHITNEY LLP 50 SOUTH SIXTH STREET SUITE 1500 MINNEAPOLIS MN 55402 LEGAL 101174 3 5380774 500762 7500 5881536 RESEARCH CONTRACT 574714 886319 886319 886319 285312 285312 163005 20320 142685 142685 142685 1223 0 1223 1223 1223 BANK REWARDS 900099 11683 11683 11683 7208758 886319 0 440903 1372060 665027 556226 150807 3647404 2576703 819325 251376 53717 24825 27194 1698 556528 379013 157635 19880 450624 186393 241049 23182 392268 197692 190218 4358 123619 62301 59945 1373 557768 299767 246869 11132 45778 28202 14980 2596 544424 391423 146428 6573 56351 32745 13200 10406 4045 2270 875 900 184894 2659 181860 375 413652 319691 88083 5878 45694 31670 13492 532 SUPPLIES 433091 342657 87921 2513 SUBCONTRACTS 383452 383452 EQUIPMENT RENT, MAINT. 149408 72554 75755 1099 LICENSES, DUES, FEES 116023 31198 68228 16597 129142 8921 61494 58727 9659942 6039163 3050777 570002 500943 621807 866892 2094179 599255 535078 21516 5634 4500 4500 130370 172587 15114291 12132886 3387557 2981405 1534819 631774 11091 11091 6158807 6760447 13215750 13818502 881967 831277 0 3959 0 2657780 4200 4200 886167 3497216 X 5300578 3469595 7029005 6851691 12329583 10321286 13215750 13818502 X -2451184 19271 423616 X 0 1 X 1 1 1 X 6597150 6134304 5162453 5105774 5881536 28881217 6597150 6134304 5162453 5105774 5881536 28881217 472747 28408470 463827 439218 467192 417906 448317 2236460 9005 6439 26068 11683 53195 31170872 907998 0.91140 0.60540 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2021 AMOUNT: $ 17. 2022 AMOUNT: $ 13,344. REBATES - 2020 AMOUNT: $ 9,005. 2021 AMOUNT: $ 6,422. 2022 AMOUNT: $ 12,724. BANK REWARDS - 2024 AMOUNT: $ 11,683. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 475000 18273 418273 75000 475000 20583 20583 475000 475000 20466 20466 475000 75000 400000 347 347 475000 75000 164 164 75000 0.00000 1.00000 0.00000 1 0 823359 823359 9701466 7937010 1764456 4589466 4195876 393590 2981405 BENEFICIAL INTEREST IN PERPETUAL TRUST 6760447 6760447 TENANT DEPOSITS 4200 4200 7849989 19271 601640 620911 7229078 -20320 -20320 7208758 9858286 198344 198344 9659942 0 9659942 PART V, LINE 4: THE ORGANIZATION'S ENDOWMENT FUNDS ARE DESIGNATED FOR USE AS OPERATING RESERVES AND SCIENTIST RECRUITMENT. PART XI, LINE 2D - OTHER ADJUSTMENTS: GAIN ON PERPETUAL TRUST 601,640. PART XI, LINE 4B - OTHER ADJUSTMENTS: RENTAL EXPENSES REPORTED ON PART VIII -20,320. PART XII, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSES REPORTED ON PART VIII 20,320. RETURN OF PRIOR YEAR GRANT FUNDING 178,024. X X X X 0 0 0 0 0 0 0 0 0 AIMEE DUDLEY PRINCIPAL INVESTIGATOR 266065 0 0 0 0 0 30500 0 0 0 296565 0 0 0 DIONNE GORDON CFAO 277618 0 0 0 0 0 9682 0 0 0 287300 0 0 0 SHANNON BOWEN CHIEF ADVANCEMENT OFFICER 240894 0 0 0 0 0 23000 0 4149 0 268043 0 0 0 LISA STUBBS PRINCIPAL INVESTIGATOR THRU 12/24 236225 0 0 0 0 0 30500 0 0 0 266725 0 0 0 JOHN FARIS CEO THRU 06/25, BOARD MEMBER 218042 0 0 0 0 0 0 0 0 0 218042 0 0 0 MICHAEL METZGER PRINCIPAL INVESTIGATOR 169445 0 0 0 0 0 23000 0 4149 0 196594 0 0 0 RICHARD MCLAUGHLIN PRINCIPAL INVESTIGATOR 170169 0 0 0 0 0 23000 0 0 0 193169 0 0 0 JUSTIN DUKES DIRECTOR IT 155685 0 0 0 0 0 11060 0 0 0 166745 0 0 0 MICHAEL KILLIAN CLINICAL DIRECTOR 148568 0 0 0 0 0 7681 0 3600 0 159849 0 0 0 LOUISE MAXWELL CHIEF COMMUNICATIONS OFFICER 135750 0 0 0 0 0 23346 0 0 0 159096 0 0 0 CLAUDIA FONSECA PRINCIPAL INVESTIGATOR 151810 0 0 0 0 0 4734 0 0 0 156544 0 0 0 SRIVIDYA VENKATESH CONTROLLER 132082 0 0 0 0 0 23000 0 0 0 155082 0 0 0 FORM 990, PART III, LINE 2 THE METZGER LAB BEGAN RESEARCH DURING FY25. FORM 990, PART III, LINE 3 THE STUBBS LAB CEASED RESEARCH IN DECEMBER OF 2024. FORM 990, PART VI, SECTION B, LINE 11B THE CEO, CFAO, CHIEF ADVANCEMENT OFFICER AND FINANCE COMMITTEE CHAIR WILL REVIEW THE FORM 990 PRIOR TO FILING WITH THE IRS. THE PUBLIC DISCLOSURE COPY WILL BE DISTRIBTED AND DISCUSSED AT A SUBSEQUENT BOARD MEETING. ELECTRONIC COPIES OF THE PUBLIC DISCLOSURE VERSION OF FORM 990 WILL BE DISTRIBUTED TO THE ENTIRE BOARD, AND PHYSICAL COPIES OF THE FULL FORM 990 WILL BE MADE AVAILABLE ONSITE UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 12C ANNUALLY, PER INSTITUTE CONFLICT OF INTEREST POLICY THE FINANCE & AUDIT COMMITTEE SUBMITS A BOARD QUESTIONNAIRE TO ALL TRUSTEES AND KEY STAFF. ALL RESPONSES ARE GATHERED AND REVIEWED BY THE COMMITTEE CHAIR AND THE CFAO. THE RESULTS ARE DISCUSSED AT THE FINANCE & AUDIT COMMITTEE MEETING. THE COMMITTEE CHAIR THEN PRESENTS THE RESULTS TO THE FULL BOARD AND ACTION IS TAKEN AS NEEDED. IF A POTENTIAL CONFLICT OF INTEREST AROSE DURING THE YEAR, THE BOARD MEMBER WOULD CONTACT OUR COMMITTEE CHAIR AND DISCLOSE THE MATTER AND BOARD REVIEW AND ACTION WOULD BE TAKEN AT THE NEXT MEETING TO ALERT ALL MEMBERS. FORM 990, PART VI, SECTION B, LINE 15 THE CEO, CFAO, AND KEY EMPLOYEES HAVE THEIR INITIAL SALARY AND ANY NON-COST OF LIVING ADJUSTMENT INCREASES DOCUMENTED BY A SALARY SURVEY PROCESS CONDUCTED BY OUR INDEPENDENT HUMAN RESOURCES CONSULTING FIRM. IN ADDITION, THE CEO CONTRACT IS APPROVED BY BOARD EXECUTIVE COMMITTEE. COMPENSATION REVIEWS ARE PERFORMED ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART XI, LINE 9: GAIN ON PERPETUAL TRUST 601,640. RETURN OF PRIOR YEAR GRANT FUNDING -178,024.